Testing ADU-1805 for advanced solid tumors safety
Treatments studied
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Women’s health & pregnancy clinical trials.
This early study tests whether ADU-1805 is safe in people with advanced solid tumors and checks how the body processes the drug. Depending on your cancer type, it may also be looking specifically at certain cancers that have not yet received PD-(L)1 immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent paperwork
- Have advanced solid cancer that is spread or cannot be removed, and is resistant to standard treatment (or no standard exists)
- Have measurable tumors that can be followed on scans (RECIST)
- Be well enough for treatment, with an ECOG performance status of 0 or 1
- Have blood counts and organ function in an acceptable range
- For the study’s specific groups, your cancer must match the listed types and prior treatment limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
This early-phase trial tests a new drug called ASD141 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if it is safe and how well it works against the cancer.
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.